Source comparison
Comparison: Tesamorelin vs Other GH Secretagogues at 1 Month
Choosing between tesamorelin, CJC-1295/ipamorelin, and MK-677 requires understanding their distinct mechanisms and early-stage effects. Tesamorelin GHRH analog. Stimulates pituitary GH release in physiological pulses IGF-1 elevation 40–80 ng/mL, 1–3% VAT reduc
This comparison does not assign a generated winner or score.
- Choosing between tesamorelin, CJC-1295/ipamorelin, and MK-677 requires understanding their distinct mechanisms and early-stage effects.
- Tesamorelin
- GHRH analog. Stimulates pituitary GH release in physiological pulses
- IGF-1 elevation 40–80 ng/mL, 1–3% VAT reduction (DEXA-measured), improved sleep architecture
- Daily subcutaneous
- Requires daily dosing; non-responders due to pituitary dysfunction see no IGF-1 rise
- CJC-1295/Ipamorelin
- GHRH analog + ghrelin mimetic (dual pathway)
- IGF-1 elevation 30–60 ng/mL, mild appetite increase, enhanced recovery from training
- 2–3x weekly
- Ipamorelin's ghrelin activity may increase hunger; less VAT-specific than tesamorelin
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist
- Moderate IGF-1 elevation (20–50 ng/mL), significant water retention (2–4 kg), increased appetite
- Daily oral (no injection)
- Water retention and hunger make fat loss harder; affects blood glucose more than GHRH analogs
- Tesamorelin's advantage is visceral fat selectivity. The published NEJM trial in HIV lipodystrophy showed 15% VAT reduction at 26 weeks versus 4% with placebo, a specificity not replicated by other secretagogues. At one month, tesamorelin produces the clearest IGF-1 response with minimal appetite disruption, making it the preferred choice when body recomposition is the primary goal. MK-677's oral convenience is offset by water retention that obscures early fat loss, while CJC-1295/ipamorelin's twice-weekly dosing appeals to users averse to daily injections but delivers less consistent GH pulsatility.